PL2611797T3 - Pochodne chinoliny lub chinazoliny o aktywności wywoływania apoptozy wobec komórek - Google Patents

Pochodne chinoliny lub chinazoliny o aktywności wywoływania apoptozy wobec komórek

Info

Publication number
PL2611797T3
PL2611797T3 PL11822135T PL11822135T PL2611797T3 PL 2611797 T3 PL2611797 T3 PL 2611797T3 PL 11822135 T PL11822135 T PL 11822135T PL 11822135 T PL11822135 T PL 11822135T PL 2611797 T3 PL2611797 T3 PL 2611797T3
Authority
PL
Poland
Prior art keywords
quinoline
cells
inducing activity
quinazoline derivatives
apoptosis inducing
Prior art date
Application number
PL11822135T
Other languages
English (en)
Inventor
In Hwan Bae
Eun Young Byun
Hae Kyoung Ju
Ji Young Song
Seung Hyun Jung
Seung Ah Jun
Ho Seok Kim
Young Hee Jung
Mi Yon Shim
Young Gil Ahn
Maeng Sup Kim
Original Assignee
Hanmi Science Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Science Co., Ltd. filed Critical Hanmi Science Co., Ltd.
Publication of PL2611797T3 publication Critical patent/PL2611797T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL11822135T 2010-08-31 2011-08-31 Pochodne chinoliny lub chinazoliny o aktywności wywoływania apoptozy wobec komórek PL2611797T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20100084731 2010-08-31
EP11822135.7A EP2611797B1 (en) 2010-08-31 2011-08-31 Quinoline or quinazoline derivatives with apoptosis inducing activity on cells

Publications (1)

Publication Number Publication Date
PL2611797T3 true PL2611797T3 (pl) 2017-05-31

Family

ID=45773391

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11822135T PL2611797T3 (pl) 2010-08-31 2011-08-31 Pochodne chinoliny lub chinazoliny o aktywności wywoływania apoptozy wobec komórek

Country Status (11)

Country Link
US (1) US8835458B2 (pl)
EP (1) EP2611797B1 (pl)
JP (1) JP5934707B2 (pl)
KR (1) KR101560227B1 (pl)
CN (1) CN103237801B (pl)
DK (1) DK2611797T3 (pl)
ES (1) ES2612472T3 (pl)
HU (1) HUE031420T2 (pl)
PL (1) PL2611797T3 (pl)
PT (1) PT2611797T (pl)
WO (1) WO2012030160A2 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102702115A (zh) * 2012-05-24 2012-10-03 盛世泰科生物医药技术(苏州)有限公司 一种4-氯-7-氟-6-硝基喹唑啉的合成方法
CN103570692A (zh) * 2013-10-31 2014-02-12 浙江大学 含吖丙啶环侧链的喹唑啉衍生物及制备和应用
CN104530063B (zh) * 2015-01-13 2017-01-18 北京赛特明强医药科技有限公司 喹唑啉并杂环类化合物及其制备方法和作为用于治疗癌症的表皮生长因子受体抑制剂的应用
CN104926737B (zh) * 2015-05-13 2017-11-07 浙江工业大学 4‑(3‑取代苯胺基)‑6‑取代基喹唑啉类化合物及制备和应用
CN104876882B (zh) * 2015-05-13 2018-05-08 浙江工业大学 6-氨基喹唑啉类化合物及应用
CN105061283B (zh) * 2015-08-09 2017-11-24 浙江大学 氨基酸苄酯盐酸盐的制备方法
CN105384699B (zh) 2015-10-23 2016-10-12 中国人民解放军南京军区南京总医院 一种新型喹唑啉衍生物lu1501及其制备方法和应用
US12503467B2 (en) * 2018-12-10 2025-12-23 Ideaya Biosciences, Inc. 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors
KR20200102948A (ko) 2019-02-22 2020-09-01 한미약품 주식회사 Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물
WO2020171649A1 (ko) * 2019-02-22 2020-08-27 한미약품 주식회사 Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물
WO2021050913A1 (en) * 2019-09-12 2021-03-18 Disarm Therapeutics, Inc. Inhibitors of sarm1
CN115210227A (zh) * 2020-03-04 2022-10-18 基因泰克公司 作为tead抑制剂的异双功能分子
CN112457260B (zh) * 2020-12-08 2023-01-17 江苏食品药品职业技术学院 N-杂环芳基喹唑啉-4-胺化合物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5230865B2 (ja) * 2004-07-15 2013-07-10 テトラロジック ファーマシューティカルズ コーポレーション Iap結合性化合物
WO2006122408A1 (en) * 2005-05-18 2006-11-23 Aegera Therapeutics Inc. Bir domain binding compounds
JP2008025888A (ja) 2006-07-19 2008-02-07 Sanyo Electric Co Ltd 低温ショーケース
PE20110217A1 (es) * 2006-08-02 2011-04-01 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
US7876313B2 (en) 2006-09-29 2011-01-25 Intel Corporation Graphics controller, display controller and method for compensating for low response time in displays
AU2007307763A1 (en) * 2006-10-12 2008-04-17 Novartis Ag Pyrrolydine derivatives as IAP inhibitors
CN101605786A (zh) * 2006-12-19 2009-12-16 健泰科生物技术公司 细胞凋亡抑制剂的咪唑并吡啶抑制剂

Also Published As

Publication number Publication date
WO2012030160A3 (en) 2012-06-28
JP2013540716A (ja) 2013-11-07
KR101560227B1 (ko) 2015-10-14
PT2611797T (pt) 2017-02-07
ES2612472T3 (es) 2017-05-17
DK2611797T3 (en) 2017-02-13
CN103237801B (zh) 2015-11-25
EP2611797A2 (en) 2013-07-10
JP5934707B2 (ja) 2016-06-15
CN103237801A (zh) 2013-08-07
US8835458B2 (en) 2014-09-16
US20130165386A1 (en) 2013-06-27
KR20130121092A (ko) 2013-11-05
EP2611797A4 (en) 2014-03-05
HUE031420T2 (en) 2017-07-28
EP2611797B1 (en) 2016-12-28
WO2012030160A2 (en) 2012-03-08

Similar Documents

Publication Publication Date Title
PT2611797T (pt) Derivados de quinolina ou de quinazolina com atividade indutora de apoptose nas células
PT3030033T (pt) Procedimento de solicitação de programação baseado no limiar e energeticamente eficiente
DK2814945T3 (da) Celle med reduceret ppgppase-aktivitet
DK2654827T3 (da) Indstillings- og forbindelsessystemer samt fremgangsmåder
DK3101127T3 (da) Alfa-amylasevarianter med forbedret stabilitet
GB201013704D0 (en) Border monitoring
IL238203A0 (en) Systems and methods for a dual oxygen center
EP2839223A4 (en) ASSEMBLY ASSEMBLIES, SOLAR FOLLOWERS AND ASSOCIATED METHODS
EP2834355A4 (en) POLYSILICATE-POLYSILICONE ENZYME IMMOBILIZATION MATERIALS
IL216763A0 (en) Probe tracking using multiple tracking methods
HRP20182046T1 (hr) Uređaj za kuhanje i postupak njegove upotrebe
LT2844751T (lt) Pagerinti chimozino fermento variantai
EP2523689A4 (en) IL-22-FC WITH HEPCIDINE EFFECT
DK2383161T3 (da) Fartøjsfront med reduceret sidevindsfølsomhed
EP2893507A4 (en) HELP WITH CLINICAL DECISION
DK2906344T3 (da) Bårne hydrobehandlingskatalysatorer med forstærket aktivitet
SG2014013866A (en) Floating structure and system
EP2534258A4 (en) KINAEDOMÄNEN WITH DOUBLE ACTIVITY AND USES THEREOF
DK3392268T3 (da) Polypeptider med transgalactosylerende aktivitet
SG11201501212QA (en) Quinazoline derivatives and uses thereof as apoptosis inhibitor
GB201218146D0 (en) The stuart angling system
AP2012006419A0 (en) Aminoquinoline derivatives
EP2802328A4 (en) TRYPTOLINE DERIVATIVES HAVING KINASE INHIBITING ACTIVITY AND USES THEREOF
DK2539328T3 (da) Vandopløselige furoxanderivater med antitumoraktivitet
PL2938623T3 (pl) Wybrane makrolidy o działaniu hamującym pde4